Skip to main content

Table 1 Patient characteristics (n = 451)

From: Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort

Characteristic Totala n(%) or mean ± SD
Sex 451  
   Female   397 (88.0%)
   Male   54 (12.0%)
Race 435  
   Caucasian   413 (94.3%)
   Asian   17 (3.9%)
   Aboriginal-Islander   8 (1.8%)
Age (years)   
   At disease onsetb 441 46.5 ± 13.7
   At recruitment 448 58.1 ± 12.4
Disease duration (years)   
   At recruitment 441 11.6 ± 10.0
   At time of the studyc 441 13.6 ± 10.3
Recruited within 2 years of SSc onsetb 451 84 (18.6%)
Recruited within 5 years of SSc onsetb 451 151 (33.5%)
Duration of follow-upc,d (years) 315 1.9 ± 0.8
Disease subtypee 451  
   Limited   319 (70.7%)
   Diffuse   132 (29.3%)
Disease manifestationsf   
   Raynaud's phenomenon 436 436 (100%)
   Digital ulcers 451 194 (43.0%)
   Tendon friction rub 451 32 (7.1%)
   Joint contractures 451 166 (36.8%)
   Highest mRSS during follow-upg 434 11.7 ± 9.6
   Synovitis 451 98 (21.7%)
   Myositis 451 4 (0.9%)
   Renal crisish 451 24 (5.4%)
   Systemic hypertensioni 444 190 (42.8%)
   Gastrointestinal involvementj 451 451 (100%)
   Pulmonary arterial hypertensionk 451 49 (10.9%)
   Interstitial lung diseasel 451 139 (30.8%)
   Cardiac involvementm 451 31 (6.9%)
Serologic profilen   
   Antinuclear antibodies 451 433 (96.0%)
   Anti-centromere pattern 450 197 (43.8%)
   Anti-RNA polymerase III antibody 451 69 (15.3%)
   Anti-topoisomerase antibodies 446 79 (17.7%)
   Anti-histidyl-tRNA synthetase antibodies 446 0 (0%)
   Anti-ribonucleoprotein antibodies 445 4 (0.9%)
   Anti-Ro antibodies 446 27 (6.1%)
   Anti-La antibodies 446 6 (1.4%)
   Anti-Smith antibodies 445 1 (0.2%)
   Anti-double-stranded DNA antibodies 298 6 (2.0%)
   Anti-polymyositis-scleroderma antibodies 447 4 (0.9%)
   Anti-neutrophil cytoplasmic antibodies 437 73 (16.7%)
Myeloperoxidase specificity 436 12 (2.8%)
Proteinase-3 specificity 436 15 (3.4%)
   Rheumatoid factor 423 126 (29.8%)
   Anti-phospholipid antibodies 436 138 (31.7%)
   Lupus anticoagulant 325 7 (2.2%)
Treatmentf 451  
   Corticosteroids   198 (43.9%)
   Antimalarialso   74 (16.4%)
   Immunosuppressivesp   143 (31.7%)
   Biological therapiesq   5 (1.1%)
Smoking ever 436 183 (42.0%)
Malignancyr 451 64 (14.2%)
   Solid organs   35 (7.8%)
   Hematopoietict   7 (1.6%)
   Skin (nonmelanoma)u   13 (2.9%)
   Melanoma   6 (1.3%)
   Otherv   3 (0.7%)
Time interval between SSc onsetw and malignancy diagnosis (years)   9.3 ± 8.1
  1. mRSS, modified Rodnan skin score; n (%), number (percentage); SD, standard deviation; SSc, systemic sclerosis. aTotal number of patients in whom data were available for analysis. bDisease onset defined as date of onset of first SSc-related manifestation other than Raynaud's phenomenon. cAs at 13 December 2010. dMean duration of follow-up calculated for those who had more than one annual visit. eDisease subtype classified based extent of skin involvement, with limited disease being confined to extremities and face. fEver from disease onset to most recent visit. gScores range from 0 to 51, with higher scores indicating more severe skin involvement. hRenal crisis defined as abrupt onset severe hypertension (systolic blood pressure (BP) ≥ 180 mmHg and/or diastolic BP ≥ 100 mmHg) without an alternate etiology, with or without rising creatinine or microangiopathic anemia. iSystolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg. jGastrointestinal involvement defined as one or more of reflux esophagitis, esophageal stricture or dysmotility, gastric antral vascular ectasia, bowel dysmotility or pseudo-obstruction. kPulmonary arterial hypertension defined as mean pulmonary arterial pressure ≥ 25 mmHg at rest with pulmonary capillary wedge pressure ≤ 15 mmHg. lInterstitial lung disease defined by high-resolution computerized tomography scan of the lung. mPresence of either left ventricular systolic or diastolic dysfunction where no other cause was identified, or a conduction disturbance unexplained by other mechanisms, or a characteristic histological picture on endomyocardial biopsy. nAt recruitment. oHydroxychloroquine. pIncludes methotrexate, azathioprine, mycophenolate mofetil, cyclosporine and cyclophosphamide. qIncludes TNF antagonists and rituximab. rEver from birth to most recent visit. sIncludes breast, lung, colorectal, genitourinary and reproductive tract malignancies. tIncludes lymphoma, leukemia and multiple myeloma. uIncludes basal cell and squamous cell carcinomas. vIncludes neoplastic variants and pre-neoplastic disorders. wHere SSc onset defined based on onset of skin change.